Overview

Systematically Transforming Cancer Immunotherapy

ImmunSYS™ is a clinical stage biopharmaceutical company focused on the development of innovative cancer immunotherapy products to improve the lives of patients with prostate cancer and other adenocarcinomas.

Our platform technology, MyVaccx™ utilizes a novel combination of a proprietary Cancer Antigen Presentation System,  a proprietary branded formulation of immunotherapeutic drugs, and a proprietary procedure developed by the focal prostate cancer pioneer and inventor of the male lumpectomy, Dr. Gary Onik. The therapy is designed to empower the immune system to selectively attack cancer cells. We are developing this new operating system for immunotherapy initially for the treatment of prostate cancer with a pipeline of additional development programs for other cancers.

The Cancer Antigen Presentation System (CAPS) is utilized to disrupt cancer cells in a way that does not damage the complex antigen structures. This enables antigen presentation to effectively expose the cancer to the immune system. A branded immunotherapy formulation is then injected directly into the tumor to mitigate the cancer’s ability to locally block immune responses against it.  The immune system is able to recognize the cancer and creates an autologous vaccine.  Lastly, the immune system is “turbo charged” with immuno-stimulatory drugs to ramp up the immune system to fight the cancer throughout the body.